Literature DB >> 10352286

Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors.

P Scognamiglio1, D Accapezzato, M A Casciaro, A Cacciani, M Artini, G Bruno, M L Chircu, J Sidney, S Southwood, S Abrignani, A Sette, V Barnaba.   

Abstract

CTL responses against multiple hepatitis C virus (HCV) epitopes were detected in 7 of 29 (24.1%) healthy family members (HFM) persistently exposed to chronically HCV-infected patients (HCV-HFM). These precursor CTL were at very low or undetectable frequencies, as determined by limiting dilution analysis. However, when HCV-specific effector CD8+ T cells, freshly isolated from PBMC of HCV-HFM, were assessed by a sensitive enzyme-linked immunospot assay, their frequencies were severalfold higher than those of precursor CTL. These results indicate that the two assays detect two functionally distinct T cell populations and that the effector cells are not assayed by the 51Cr-release assay. Furthermore, the combination of cell depletion and enzyme-linked immunospot analyses showed that the effector cells were confined into a CD8+ CD45RO+ CD28- population. The persistence of effector CD8+ T cells specific for both the structural and nonstructural viral proteins in uninfected HCV-HFM, suggest that: 1) an immunological memory is established upon a subclinical infection without any evidence of hepatitis, in a large cohort of HCV-exposed individuals; 2) because these cells required neither restimulation nor the addition of particular cytokines in vitro for differentiating in effectors, they should be capable of prompt HCV-specific effector function in vivo, possibly providing antiviral protection; and 3) the maintenance of effector T cell responses may be sustained by persisting low-level stimulation induced by inapparent infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

3.  Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.

Authors:  Shihong Zhang; Rakesh K Bakshi; Pothakamuri Venkata Suneetha; Paraskevi Fytili; Dinler A Antunes; Gustavo F Vieira; Roland Jacobs; Christoph S Klade; Michael P Manns; Anke R M Kraft; Heiner Wedemeyer; Verena Schlaphoff; Markus Cornberg
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection.

Authors:  Josep Quer; Juan Ignacio Esteban; Joan Cos; Sílvia Sauleda; Laura Ocaña; María Martell; Teresa Otero; Maria Cubero; Eduard Palou; Pedro Murillo; Rafael Esteban; Jaume Guàrdia
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.

Authors:  Sayed F Abdelwahab; Zainab Zakaria; Maha Sobhy; Eman Rewisha; Mohamed A Mahmoud; Mahmoud A Amer; Mariarosaria Del Sorbo; Stefania Capone; Alfredo Nicosia; Antonella Folgori; Mohamed Hashem; Samer S El-Kamary
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

7.  Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study.

Authors:  Theo Heller; Jens Martin Werner; Fareed Rahman; Eishiro Mizukoshi; Yuji Sobao; Ann Marie Gordon; Arlene Sheets; Averell H Sherker; Ellen Kessler; Kathleen S Bean; Steven K Herrine; M'lou Stevens; James Schmitt; Barbara Rehermann
Journal:  J Infect Dis       Date:  2013-06-24       Impact factor: 5.226

8.  Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.

Authors:  H Wedemeyer; E Mizukoshi; A R Davis; J R Bennink; B Rehermann
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

9.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

10.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.